Arcus Biosciences
arcus biosciences's email is webmaster@arcusbio.com
and
arcus biosciences's phone number is +1 510-694-6200
.
Arcus Biosciences is an oncology-focused clinical-stage biopharmaceutical company that discovers, develops, and commercializes novel therapies for the treatment of cancer. It aims to create new cancer therapeutics through the utilization of emerging insights in immunology. The company has four molecules in clinical development: Etrumadenant (AB928), the first dual A2a/A2b adenosine receptor antagonist to enter the clinic, is being evaluated in multiple Phase 2 and 1b studies across different indications, including prostate, colorectal, non-small cell lung, pancreatic and...
read more
Arcus Biosciences is an oncology-focused clinical-stage biopharmaceutical company that discovers, develops, and commercializes novel therapies for the treatment of cancer. It aims to create new cancer therapeutics through the utilization of emerging insights in immunology. The company has four molecules in clinical development: Etrumadenant (AB928), the first dual A2a/A2b adenosine receptor antagonist to enter the clinic, is being evaluated in multiple Phase 2 and 1b studies across different indications, including prostate, colorectal, non-small cell lung, pancreatic and triple-negative breast cancers. AB680, the first small-molecule CD73 inhibitor to enter the clinic, is in Phase 1/1b development for first-line treatment of metastatic pancreatic cancer in combination with zimberelimab and gemcitabine/nab-paclitaxel. Domvanalimab (AB154), an anti-TIGIT monoclonal antibody and new potential immuno-oncology backbone therapy, is in a three-arm randomized Phase 2 study for first-line treatment of PD-L1-high metastatic non-small cell lung cancer (NSCLC) evaluating zimberelimab monotherapy, domvanalimab with zimberelimab and domvanalimab plus AB928 with zimberelimab. AB308, an anti-TIGIT antibody that is FcR enabled, is advancing into clinical development to investigate additional indications, with a focus on hematological malignancies. Zimberelimab (AB122), Arcus’s anti-PD-1 monoclonal antibody, was in-licensed to enable the development of Arcus’s combination regimens and is being evaluated in various combinations across the portfolio. Arcus was formed in 2015 in Hayward, California by Terry Rosen and Juan Jaen.
show less
Website | arcusbio.com | |
Industry | Biotechnology | |
Location | Hayward, California, United States | |
Founded | 2015 |
HQ | 3928 Point Eden Way | |
Phone | +1 510-694-6200 | |
webmaster@arcusbio.com | ||
Funding | 647,050,000 USD |
Website | ||
Industry | Biotechnology | |
Employees | 183 | |
Founded | 2015 | |
HQ | 3928 Point Eden Way | |
Phone | +1 510-694-6200 | |
webmaster@arcusbio.com | ||
Funding | 647050000 |
Top Competitor for Arcus Biosciences
Arcus Biosciences Questions
Where are arcus biosciences's headquarters?
arcus biosciences's headquarters are in 3928 Point Eden Way
What is arcus biosciences's phone number?
arcus biosciences's phone number is +1 510-694-6200
What is arcus biosciences's official website?
arcus biosciences's website is arcusbio.com
How many employees are working in arcus biosciences right now?
arcus biosciences has
183 employees.
View the Email and Phone Numbers for all 183 working at arcus biosciences.
What is arcus biosciences's industry?
arcus biosciences's industry is
Biotechnology
Who are arcus biosciences's top competitors?
arcus biosciences's top competitors are
Roche
,
Agilent Technologies
,
Amgen
,
Genentech
,
Eurofins
,
Gilead Sciences
,
Lonza
,
Charles River Laboratories
,
Sanofi Genzyme
,
Biogen
What is arcus biosciences's email address?
arcus biosciences's email address is webmaster@arcusbio.com
What are arcus biosciences's categories?
arcus biosciences's categories are Biotechnology, Health Care, Medical, Therapeutics
What is arcus biosciences's location?
arcus biosciences's location is
Hayward, California, United States
When was arcus biosciences founded?
arcus biosciences's founding year is 2015
What is arcus biosciences's funding?
arcus biosciences's funding is -
What is arcus biosciences's current status?
arcus biosciences's current status is ipo
Top Arcus Biosciences Employees
Senior Research And Development Protein Sciences
amberpham2001@yahoo.com
+1772-807-5100
Senior Manager, Data Management
jackie.hawk@gilead.com
+1206-832-2115
Associate Director, Research Informatics
scott.silveria@gmail.com
+1510-420-6700
Senior Director Regulatory Operations
lisa.owens@gilead.com
+1203-315-1222
Vice President Finance
alexander.azoy@warnerbros.com
+1818-606-4246
Senior Director, Antibody Product And Analytical Sciences
kunnel.babu@merck.com
+1908-740-4000
Senior Scientist
elaine.ginn@novartis.com
+1510-923-5033
Senior Clinical Data Manager
dkoltenback31@gmail.com
+1267-614-1850